← All trials
NCT04439045
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 14, 2020
- Primary completion
- Apr 1, 2021
- Completion date
- Jun 1, 2021
- First posted
- Jun 19, 2020
- Last posted
- Jun 19, 2020
- Enrollment
- 3626
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of TorontoLead sponsor
- Max Planck InstituteCollaborator
- University of TorontoOverall official - principal investigator
- Serum Institute of India Pvt. Ltd.Collaborator
- Verity PharmaceuticalsCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.